BioCentury | Aug 11, 2017
Emerging Company Profile

Infecting tumors

...programs have shown limited efficacy using Salmonella -based vectors to treat cancer. In 2002, now-defunct Vion Pharmaceuticals Inc....
BioCentury | Mar 23, 2017
Translation in Brief

Salmonella-1, tumors-0

...for delivering cancer therapies because the microbes target the hypoxic tumor microenvironment. In 2002, now-defunct Vion Pharmaceuticals Inc....
BioCentury | May 19, 2011
Distillery Techniques

Technology: Drug platforms

...trials of the combination. The Stat3 knockdown strain used in the study was developed by Vion Pharmaceuticals Inc....
BioCentury | Feb 14, 2011
Regulation

Decelerated approval

...companies could not show a benefit over existing treatments. The drugs were Onrigin laromustine from Vion Pharmaceuticals Inc....
...Chicago Medical Center , Chicago, Ill. U.S. Food and Drug Administration (FDA), Silver Spring, Md. Vion...
BioCentury | Mar 8, 2010
Clinical News

Onrigin laromustine regulatory update

...leukemia (AML) prior to conducting another Phase III trial. In January, FDA refused to grant Vion...
...additional trial (see BioCentury, Dec. 21). Vion filed for Chapter 11 bankruptcy late last year. Vion Pharmaceuticals Inc....
BioCentury | Jan 11, 2010
Clinical News

Laromustine regulatory update

...FDA refused to grant Vion an SPA for a planned Phase III trial (HOVON AML 92...
...complete response letter from FDA for Onrigin to treat AML (see BioCentury, Dec. 21, 2009). Vion Pharmaceuticals Inc....
BioCentury | Jan 4, 2010
Finance

4Q setbacks

...risk of residual effects when Intermezzo is taken in the middle of the night Vion Pharmaceuticals Inc. (OTCBB:VION...
BioCentury | Dec 21, 2009
Clinical News

Onrigin laromustine regulatory update

...that the company conduct an additional randomized trial and addressed clinical pharmacology and manufacturing issues. Vion...
...would be needed for the sulfonyl hydrazine DNA alkylating agent (see BioCentury, Sept. 7). Vion Pharmaceuticals Inc. (OTCBB:VION...
BioCentury | Dec 21, 2009
Company News

Vion cancer news

...had previously said that it does not have sufficient funds for a new randomized trial. Vion...
...II testing for myeloproliferative disorders and Phase I testing for solid tumors. At Sept. 30, Vion...
...in cash and a nine-month operating loss of $14.1 million (see BioCentury, Oct. 19). Vion Pharmaceuticals Inc. (OTCBB:VION...
BioCentury | Dec 21, 2009
Finance

Ebb & Flow

...profile for Hexvix to detect papillary bladder cancer using fluorescence cystoscopy (see B14) . Vion Pharmaceuticals Inc. (OTCBB:VION...
...FDA issued a complete response letter to an NDA for Onrigin laromustine. The agency asked Vion...
...ages 60 and up with de novo, poor-risk acute myelogenous leukemia (AML). For the week, Vion...
Items per page:
1 - 10 of 259
BioCentury | Aug 11, 2017
Emerging Company Profile

Infecting tumors

...programs have shown limited efficacy using Salmonella -based vectors to treat cancer. In 2002, now-defunct Vion Pharmaceuticals Inc....
BioCentury | Mar 23, 2017
Translation in Brief

Salmonella-1, tumors-0

...for delivering cancer therapies because the microbes target the hypoxic tumor microenvironment. In 2002, now-defunct Vion Pharmaceuticals Inc....
BioCentury | May 19, 2011
Distillery Techniques

Technology: Drug platforms

...trials of the combination. The Stat3 knockdown strain used in the study was developed by Vion Pharmaceuticals Inc....
BioCentury | Feb 14, 2011
Regulation

Decelerated approval

...companies could not show a benefit over existing treatments. The drugs were Onrigin laromustine from Vion Pharmaceuticals Inc....
...Chicago Medical Center , Chicago, Ill. U.S. Food and Drug Administration (FDA), Silver Spring, Md. Vion...
BioCentury | Mar 8, 2010
Clinical News

Onrigin laromustine regulatory update

...leukemia (AML) prior to conducting another Phase III trial. In January, FDA refused to grant Vion...
...additional trial (see BioCentury, Dec. 21). Vion filed for Chapter 11 bankruptcy late last year. Vion Pharmaceuticals Inc....
BioCentury | Jan 11, 2010
Clinical News

Laromustine regulatory update

...FDA refused to grant Vion an SPA for a planned Phase III trial (HOVON AML 92...
...complete response letter from FDA for Onrigin to treat AML (see BioCentury, Dec. 21, 2009). Vion Pharmaceuticals Inc....
BioCentury | Jan 4, 2010
Finance

4Q setbacks

...risk of residual effects when Intermezzo is taken in the middle of the night Vion Pharmaceuticals Inc. (OTCBB:VION...
BioCentury | Dec 21, 2009
Clinical News

Onrigin laromustine regulatory update

...that the company conduct an additional randomized trial and addressed clinical pharmacology and manufacturing issues. Vion...
...would be needed for the sulfonyl hydrazine DNA alkylating agent (see BioCentury, Sept. 7). Vion Pharmaceuticals Inc. (OTCBB:VION...
BioCentury | Dec 21, 2009
Company News

Vion cancer news

...had previously said that it does not have sufficient funds for a new randomized trial. Vion...
...II testing for myeloproliferative disorders and Phase I testing for solid tumors. At Sept. 30, Vion...
...in cash and a nine-month operating loss of $14.1 million (see BioCentury, Oct. 19). Vion Pharmaceuticals Inc. (OTCBB:VION...
BioCentury | Dec 21, 2009
Finance

Ebb & Flow

...profile for Hexvix to detect papillary bladder cancer using fluorescence cystoscopy (see B14) . Vion Pharmaceuticals Inc. (OTCBB:VION...
...FDA issued a complete response letter to an NDA for Onrigin laromustine. The agency asked Vion...
...ages 60 and up with de novo, poor-risk acute myelogenous leukemia (AML). For the week, Vion...
Items per page:
1 - 10 of 259